...
机译:复发/难治性DLBCL中的Avadomide单疗法:安全性,疗效和预测基因分类器
Univ Autonoma Barcelona Univ Hosp Vall Hebron Vall Hebron Inst Oncol Dept Hematol Barcelona;
Inst Paoli Calmettes Marseille France;
CHU Toulouse Toulouse France;
Hosp Badalona Germans Trias &
Pujol Josep Carreras Leukaemia Res Inst IJC ICO Badalona Spain;
Ctr Hosp Lyon Sud Pierre Benite France;
Hosp Univ Fdn Jimenez Diaz Madrid Spain;
IRCCS Fdn G Pascale Ist Nazl Tumor Naples Italy;
Rutgers Canc Inst New Jersey New Brunswick NJ USA;
South Texas Accelerated Res Therapeut LLC San Antonio TX USA;
Clin Univ Navarra Pamplona Spain;
Grp Espanol Terapias Inmunobiol Canc GETICA 12 Octubre Univ Hosp &
Res Inst Madrid Spain;
Humanitas Res Hosp &
Canc Ctr Milan Rozzano Italy;
Hosp del Mar Barcelona Spain;
Fdn IRCCS Milan Italy;
Hosp Univ Salamanca Salamanca Spain;
UZ Gasthuisberg Leuven Leuven Belgium;
Univ Louvain Clin Univ St Luc Brussels Belgium;
Bristol Myers Squibb San Diego CA USA;
Genmab Pharmaceut Princeton NJ USA;
Bristol Myers Squibb San Diego CA USA;
British Columbia Canc Agcy Terry Fox Lab Vancouver BC Canada;
British Columbia Canc Agcy Terry Fox Lab Vancouver BC Canada;
Fred Hutchinson Canc Res Ctr 1124 Columbia St Seattle WA 98104 USA;
Bristol Myers Squibb Berkeley Hts NJ USA;
Bristol Myers Squibb San Francisco CA USA;
Celgene Inst Translat Res Europe Seville Spain;
Celgene Inst Translat Res Europe Seville Spain;
Bristol Myers Squibb San Francisco CA USA;
Bristol Myers Squibb Summit NJ USA;
Bristol Myers Squibb Summit NJ USA;
Bristol Myers Squibb San Francisco CA USA;
Inst Gustave Roussy Villejuif France;
机译:复发/难治性DLBCL中的Avadomide单疗法:安全性,疗效和预测基因分类器
机译:II期研究,以评估双MTORC1 / 2抑制剂Vistusertib在复发,难治性DLBCL中的安全性和功效
机译:Tisagenlecleuel治疗在复发/难治性弥漫性大型B细胞淋巴瘤(R / R DLBCL)患者中的安全性和有效性,并且在朱丽叶试验桥接化疗后没有积极疾病的证据
机译:用于预测乳腺癌复发的基因选择的混合进化框架
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:尼古鲁单抗治疗后复发/难治性霍奇金淋巴瘤患者尼古鲁单抗和苯达莫司汀(NB)的安全性和有效性研究
机译:Carpio C,Bouabdallah R,YSEBAERT L等。复发/难治性DLBCL中的Avadomide单疗法:安全性,疗效和预测基因分类器。血液。 2020; 135(13):996-1007。